Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population
| Autor: | Aynur Oguz, Ebru Yilmaz Keskin, Melek Isik, Hülya Kayilioğlu, Idil Yenicesu, Ülker Koçak, Fatma Burcu Belen, Derya Kan Karaer, Arzu Okur, Meryem Albayrak, Ertan Sal, Faruk Güçlü Pınarlı, Funda Tekkeşin, Ceyda Karadeniz, Nergiz Oner, E F Percin, Zühre Kaya, Türkiz Gürsel |
|---|---|
| Přispěvatelé: | Kırıkkale Üniversitesi |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Neurotoxicity Syndrome Turkish population Vincristine CYP3A5 Adolescent Genotype Turkey medicine.medical_treatment Pharmacology Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Neoplasms Medicine genetic polymorphism Cytochrome P-450 CYP3A Humans Adverse effect Child Chemotherapy Dose-Response Relationship Drug business.industry Case-control study Neurotoxicity Infant Hematology Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Antineoplastic Agents Phytogenic Oncology 030220 oncology & carcinogenesis Case-Control Studies Child Preschool Pediatrics Perinatology and Child Health Neurotoxicity Syndromes business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of pediatric hematology/oncology. 39(6) |
| ISSN: | 1536-3678 |
| Popis: | Pinarli, Faruk Guclu/0000-0002-3241-2478; Albayrak, Meryem/0000-0003-2711-5150 WOS: 000406231400018 PubMed: 28697165 Vincristine is a widely used chemotherapeutic agent in the treatment of childhood malignancies. Neuropathy is the most common adverse effect. CYP3A4 and CYP3A5 enzymes of cytochrome p450 enzyme system are responsible in vincristine metabolism. Genetic polymorphism may alter the vincristine metabolism and the neurotoxicity rate. In this study, distribution of CYP3A5 alleles among Turkish children with malignancies, relation between CYP3A5 genotype and neurotoxicity rates, as well as severity and duration of neuropathy and total vincristine doses were investigated. Patient group consisted of 115 patients (age, 1 to 17 y) with acute lymphoblastic leukemia and solid tumors, who were treated with vincristine consisting chemotherapy protocols. Control group consisted of 50 children without any neurological symptom or disorders. All patient files were reviewed for presence and severeness of neurotoxicity symptoms. Blood samples were obtained and CYP3A5 genotypes were analyzed. Neurotoxicity occurred in 20.8% of patients. Although it was found to occur more frequently after 4 doses of vincristine, and rates were higher in the low-dose vincristine group suggesting other contributing factors. Although neurotoxicity rate in the CYP3A5*1/*3 genotype was 17.6%, it was 21.6% in the CYP3A5*3/*3 genotype and the difference was not statistically significant (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|